{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025827","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.722134+00:00","generated_at":"2026-05-17T16:01:39.230270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCardia Q2 net loss $2M, cash ~$1.1M after ATM; runway into Oct 2025","bullets":["Net loss of $2.0M for Q2 2025 vs $1.6M in Q2 2024; R&D expenses up to $1.4M.","Cash balance $980k at June 30; raised $769k via ATM at avg $2.59/share; runway into Oct 2025.","R&D expenses increased due to closeout of CardiAMP HF trial and start of CardiAMP HF II enrollment.","Phase 3 CardiAMP HF data submitted to Japan PMDA; FDA meetings on approvability expected Q4 2025.","Helix transendocardial delivery system DeNovo 510(k) submission planned Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025827","json":"https://secwatch.observer/filing/0001437749-25-025827.json","markdown":"https://secwatch.observer/filing/0001437749-25-025827.md","text":"https://secwatch.observer/filing/0001437749-25-025827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/0001437749-25-025827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/bcda20250811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:01:39.230270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}